Biotech Values

[pcrutch]

Thanks for the link.

Agree that the low separation between Oxy and placebo is somewhat surprising. Not sure what the dosing for Oxy was in this trial. I imagine the Oxy and 797 are fairly close, which is quite encouraging.

Hopefully ARRY's fantastic biz development team partners this in the next 6-9 months. Seems like an opportunity for someone with bigger pockets to explore in Phase 3 given the amount of data they have on this drug.